Foot Ulcer Chronic, Pressure Ulcer, Skin Ulcer Venous Stasis Chronic
Conditions
Brief summary
This investigation plans to initiate the healing of chronic wounds by providing a concentrated platelet and growth factor therapy directly to the wound site by topical delivery. This therapy will be derived from autologous platelet rich plasma (PRP), an emerging surgical and wound care treatment. This investigation aims to demonstrate that patients with chronic, non-healing wounds treated with autologous PRP and standard medical care have a reduction in wound volume and improved healing rate that results in patient-centered clinically significant health outcomes as compared to patients treated with standard medical care only.
Detailed description
This is a multicenter randomized controlled trial, with a single-blind parallel design. 1,500 subjects are planned to enroll in the study. Each subject will be assigned to the treatments in random order. The stratified permuted block randomization method will be applied to the patient assignment. In addition to three study populations, i.e., DFU, VU and PU, and study centers, stratification will be based on one overall variable, (1) nutritional status (Low: Prealbumin \<12mg/d vs. moderate: Prealbumin \>= 12 mg/d) and one variable for each wound type. Diabetic food ulcer will be based on offloading (2a) (Specialty shoes vs. Total contact cast), pressure ulcer will be based on offloading (2b) (mattress vs. cushion), and venous leg ulcer will be based on compression (2c)(Low: \<10 mmHG vs. High: \>=30mmHG). Randomization will proceed within strata according to a permuted block scheme with a block size, or balancing interval, varying randomly between 2, 4 or 6. The primary endpoint will be evaluated by a blinded physician to avoid the bias. Total duration of each patient in the study is expected to be 20 weeks.
Interventions
PROCEDUREPlatelet Rich Plasma
Patients will receive weekly PRP treatments with standard of care.
PROCEDUREStandard of Care
Patients will receive weekly standard of care.
Sponsors
ACR Biologics, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
6.2 Inclusion Criteria * Male or female ≥ 18 years of age. * Wound must be diagnosed as Diabetic Foot Ulcers (DFU), Venous Ulcers (VU), or Pressure Ulcers (PU) with duration greater than 30 days at first visit/patient screening. * If more than one non-healing wound is present, the largest wound will be selected and must be at least 2cm in size. * Wound must be classified as Wagner 1 - 3 on the Wagner classification system. Wagner's Classification System Grade 1 Superficial ulcer without subcutaneous tissue involvement Grade 2 Penetration through the subcutaneous tissue (bone, tendon, ligament or joint capsule) Grade 3 Osteitis, abscess or osteomyelitis Grade 4 Gangrene of the forefoot Grade 5 Gangrene of the entire foot * There must be at least 2 cm between the index wound and other wounds; if all wounds are closer than 2 cm, the patient should not be enrolled (screen failure). * Wound must be clinically non-infected (A swab or deep tissue culture shall be performed at the discretion of the provider). * If a female of childbearing potential, the patient must have a negative serum pregnancy test at screening. * Patient has the capacity to understand and consent to be in the study. Written informed consent must be obtained from either the patient or the patient's legally acceptable representative prior to screening activities. * Platelet count ≥ 75,000 (according to CBC) * Hemoglobin (Hgb) level \> 9 g/dL (according to CBC) * Hematocrit (HCT or Ht) level \> 27% (according to CBC) * Ankle-Brachial Index (ABI) Test \> 0.7 6.3
Exclusion criteria
* Male or female \<18 years of age * Patients with known sensitivity to components of the PRP kit (calcium chloride, thrombin, collagen, acid citrate dextrose solution A (ACDA). * Wound is not a Diabetic Foot Ulcers (DFU), Venous Ulcer (VU), or Pressure Ulcer (PU) at duration of greater than 30 days at first visit/patient screening. * Wounds smaller than 2cm will be excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Wound Closure | 20 weeks | The primary objective of this trial is to evaluate increasing the proportion of wounds with complete closure within 20 weeks of initial treatment |
Countries
United States
Outcome results
None listed